Your browser doesn't support javascript.
loading
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
Warren, R B; Blauvelt, A; Poulin, Y; Beeck, S; Kelly, M; Wu, T; Geng, Z; Paul, C.
Afiliação
  • Warren RB; The Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, Manchester, UK.
  • Blauvelt A; Oregon Medical Research Centre, Portland, OR, USA.
  • Poulin Y; Laval University and Centre de Recherche Dermatologique du Québec Métropolitain, Québec City, QC, Canada.
  • Beeck S; AbbVie Inc., North Chicago, IL, USA.
  • Kelly M; AbbVie Inc., North Chicago, IL, USA.
  • Wu T; AbbVie Inc., North Chicago, IL, USA.
  • Geng Z; AbbVie Inc., North Chicago, IL, USA.
  • Paul C; Paul Sabatier University and Larrey Hospital, Toulouse, France.
Br J Dermatol ; 184(1): 50-59, 2021 01.
Article em En | MEDLINE | ID: mdl-32594522
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Qualidade de Vida Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Qualidade de Vida Idioma: En Ano de publicação: 2021 Tipo de documento: Article